Last Updated: 2018-10-04
By Will Boggs MD
NEW YORK (Reuters Health) - The risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) treated with tenofovir is lower than in those treated with entecavir, according to a nationwide study from South Korea.
"Patients with CHB have about 1% risk of developing HCC," Dr. Young-Suk Lim from the University of Ulsan College of Medicine, in Seoul, told Reuters Health by email. "Once diagnosed with HCC, the overall prognosis of the patients is very poor, with 5-year survival rate of less than 30%. Therefore, prevention of HCC is of utmost importance in the management of CHB patients."
Entecavir and tenofovir disoproxil fumarate (TDF), first-line antiviral agents for CHB infection, have similar efficacy for intermediate-term virologic, biochemical, serologic and histologic outcomes. Their relative efficacy in reducing HCC risk remains uncertain.
During follow-up, the incidence of HCC was significantly lower in the tenofovir group (0.64 per 100 person-years) than in the entecavir group (1.06 per 100 person-years), the researchers report in JAMA Oncology, online September 27....
Read the complete article here:
In The Journal
JAMA Oncology, online September 27:
doi:10.1001/jamaoncol.2018.4070
doi:10.1001/jamaoncol.2018.4039
No comments:
Post a Comment